৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Active immunization against Hepatitis A virus. \r\nHepatitis A vaccine is used to prevent, hepatitis A
Hepatitis A vaccine should be given intramuscularly only.
Intramuscular\r\nActive immunisation against hepatitis A\r\nAdult: \r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\n
Intramuscular\r\nActive immunisation against hepatitis A\r\nChildren of 1 year of age \r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\nChildren 12 months to 15 years: The recommended dose is 0.5 ml\r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\nChildren 16 years and above: The recommended dose is 1 ml\r\nFirst dose: At elected date \r\nSecond dose: 6 months after first dose
Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.
Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.
Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.\r\nThe vaccine should be given to a pregnant woman only if clearly needed.\r\n\r\nLactation: not established
>10%\r\nInjection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%),Irritability (11-36%),Anorexia (1-19%),Drowsiness (15-17%),Headache (1-16%),Fever > 100.4 F (9-11%)\r\n\r\n1-10%\r\nURI (1-10%),Otitis media (8%),Rhinorrhea (6%),Diarrhea (1-6%),Cough (1-5%),Rash (1-5%),Weakness/fatigue (4%),Vomiting (1-4%),Fever > 102 F (3%),Crying (2%)\r\n\r\n<1%\r\nHematoma,Incr. CPK,Photophobia,Vertigo\r\n\r\nPotentially Fatal: Anaphylaxis.
Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Active immunization against Hepatitis A virus. \r\nHepatitis A vaccine is used to prevent, hepatitis A
Hepatitis A vaccine should be given intramuscularly only.
Intramuscular\r\nActive immunisation against hepatitis A\r\nAdult: \r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\n
Intramuscular\r\nActive immunisation against hepatitis A\r\nChildren of 1 year of age \r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\nChildren 12 months to 15 years: The recommended dose is 0.5 ml\r\nFirst dose: At selected date \r\nSecond dose: 6 months after first dose\r\n\r\nChildren 16 years and above: The recommended dose is 1 ml\r\nFirst dose: At elected date \r\nSecond dose: 6 months after first dose
Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.
Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.
Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.\r\nThe vaccine should be given to a pregnant woman only if clearly needed.\r\n\r\nLactation: not established
>10%\r\nInjection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%),Irritability (11-36%),Anorexia (1-19%),Drowsiness (15-17%),Headache (1-16%),Fever > 100.4 F (9-11%)\r\n\r\n1-10%\r\nURI (1-10%),Otitis media (8%),Rhinorrhea (6%),Diarrhea (1-6%),Cough (1-5%),Rash (1-5%),Weakness/fatigue (4%),Vomiting (1-4%),Fever > 102 F (3%),Crying (2%)\r\n\r\n<1%\r\nHematoma,Incr. CPK,Photophobia,Vertigo\r\n\r\nPotentially Fatal: Anaphylaxis.
Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.






N/A
